Scientific Advisory Board
David Perlin, Ph.D.
Executive Director and Professor of the Public Health Research Institute at Rutgers
Director of the Rutgers Regional Biocontainment Laboratory
Director of Public Health Research Institute of New Jersey
Fellow at The New York Academy of Sciences
Executive Director of the Rutgers-New Jersey Medical School’s Public Health Research Institute (PHRI), a 73-year-old specialized center for global infectious disease research.
He is also Director of the new Rutgers Regional Biocontainment Laboratory, one of thirteen NIH-designated national centers, and a Professor of Microbiology and Molecular Genetics. Dr. Perlin helped establish PHRI as a leading center for tuberculosis and opportunistic infections research. He has published more than 215 papers and book chapters and has co-authored two books. His laboratory is supported by grants from the NIH, pharma and biotech sectors. He is on the editorial board of several scientific journals and serves on the Board of Directors of the Aaron Diamond AIDS Research Center, and Scientific/Medical Advisory Boards for the CLSI, LIFE, pharma and biotech companies, and PinnacleCare.
Dr. Perlin earned an AB degree from Brandeis University in 1976 and a Ph.D. from Cornell University in 1980. He pursued postdoctoral studies at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry. Dr. Perlin joined PHRI in 1985; he was named Scientific Director in 1992, President in 2005, and Director of the new UMDNJ Center in 2006. He was appointed Professor of Microbiology and Molecular Genetics in 2003 and Executive Director of PHRI and the Rutgers Regional Biocontainment Laboratory in 2010. Dr. Perlin was named a Fellow of the New York Academy of Sciences in 2005, and a Visiting Professor at the University of Manchester, UK in 2009.
Jeffrey Henderson, Ph.D., MD
Assistant Professor of Medicine and Molecular Microbiology
Division of Infectious Diseases
Washington University School of Medicine
Assistant Professor Departments of Internal Medicine, Infectious Disease, Molecular Microbiology and Center for Women’s Infectious Diseases (cWIDR) at the Washington University School of Medicine, in St. Louis, MO. Dr. Henderson holds leadership roles with the Biochemistry Program and Molecular Microbiology and Microbial Pathogenesis Programs. His research area of interest includes pathophysiology of enteric Gram-negative infections with a special focus on pathogenic interactions with transition metals.
Dr. Henderson holds board certifications in Infectious Disease and Internal Medicine. He received a bachelor of science, with honors, in Chemistry from the University of Wisconsin, his medical degree and a Ph.D. in Molecular Biophysics from the Washington University School of Medicine, St. Louis, MO. His postgraduate training included an Internal Medicine residency and Infectious Diseases fellowship at Barnes-Jewish Hospital/Washington University. He is an NIH principal investigator, co-investigator, and collaborator on multiple infectious diseases research projects involving translation between basic and clinical research. He has published over forty peer-reviewed studies and served as a reviewer for multiple journals including the Proceedings of the National Academy of Sciences, U.S.A., PLoS Pathogens, ACS Infectious Diseases, Infection and Immunity, and Journal of Bacteriology. Dr. Henderson has been an invited lecturer at the National Institutes of Health, Gordon Research Conferences, and medical grand rounds. His professional affiliations include the Infectious Diseases Society of America, American Society for Microbiology, and the American Society for Biochemistry and Molecular Biology.
David Andes, MD
Professor Medicine and of Medical Microbiology and Immunology
Division of Infectious Diseases and Medical Microbiology and Immunology
Head of the Division of Infectious Disease and Director of the Infectious Disease Fellowship Program
University of Wisconsin School of Medicine and Public Health
Professor Medicine and of Medical Microbiology and Immunology at the University of Wisconsin School of Medicine and Public Health in Madison, WI. Head of the Division of Infectious Disease and Director of the Infectious Disease Fellowship Program. The focus of Dr. Andes' research programs involves the identification of strategies to combat antimicrobial (especially antifungal) drug resistance. Study approaches include defining the molecular basis for drug resistance, drug target development, pharmacodynamic investigation, and clinical trial study of resistance epidemiology.
Dr. Andes has authored many publications, serves as editor of Antimicrobial Agents and Chemotherapy, and is an editorial board member for a number of other prestigious journals. He is past president of the International Society of Antimicrobial Pharmacology. After receiving a bachelor of arts in biology from St. Louis University, Missouri, Dr. Andes completed his medical degree at the University of Missouri, in Columbia. His postgraduate training included a residency in internal medicine, chief residency, and clinical fellowship in infectious disease at the University of Wisconsin, Madison. He has research training in antimicrobial pharmacodynamics, molecular biology, and molecular mycology. A principal investigator, co-investigator, and collaborator on a number of research projects on infectious diseases and their treatment, Dr. Andes' publications include co-authoring book chapters, abstracts, and articles in such journals as Antimicrobial Agents and Chemotherapy, Current Opinion in Infectious Disease, and Clinical Infectious Diseases. He serves on the Editorial Board on Antimicrobial Agents and Chemotherapy and as an ad hoc reviewer for many journals including Clinical Pharmacokinetics, Clinical Microbiology and Infection, Mayo Clinic Proceedings, Medical Mycology, and Clinical Infectious Diseases. Dr. Andes has been an invited lecturer at grand rounds, and local and regional medical education seminars and has made numerous presentations at national and international symposia and conferences. Honored for both his academic and research contributions to medicine, Dr. Andes is active on hospital and research committees as well as in professional medical associations. He is the treasurer of the International Society of Anti-infective Pharmacology. His professional affiliations also include the International Society of Antimicrobial Pharmacology, American Society of Microbiology, American College of Physicians, and European Society of Clinical Microbiology and Infectious Diseases.
Nathan Keller, MD, Ph.D., EMBA
Sheba Medical Center
Director of Clinical Biology
Head of the Laboratory Center
Director of the Clinical Microbiology Department at the Chaim Sheba Medical Center, Tel Hashomer, Israel. He also serves as the chairperson of the Israeli Society for Infectious Disease and has held this position since 2012. Dr. Keller has served in the Israeli military and received his Doctor of Medicine degree from Hebrew University in Jerusalem. Dr. Keller holds an executive MBA degree and a Ph.D. in medical microbiology. He continues to be a lecturer and associate professor in medical epidemiology at the Ariel University Center of Samaria, Ariel, Israel. Dr. Keller’s primary focus in research is microbiology and has presented at scientific meetings around the world. Dr. Keller has co-authored and published over 100 articles. Dr. Keller’s professional affiliations include the American Society of Microbiology, the Israel Society of Infectious Disease, the Israel Medical Association, and the Immuno Compromised Society.
Daniel Perl, MD, Ph.D.
US Public Health Service, Centers for Disease Control
Brown University Medical School
Mount Sinai School of Medicine
Director of the Neuropathology Division
Professor of Pathology, Psychiatry and Neurosciences.
Dr. Daniel Perl was born and raised in New York City and received his undergraduate degree from Columbia and his medical training at the State University of New York, Downstate Medical Center. He then took postgraduate training in Anatomic Pathology and Neuropathology at Yale University, following which he served for two years as a pathologist in the US Public Health Service, stationed at the Centers for Disease Control in Atlanta, Georgia. In subsequent years he served on the faculty of the Brown University Medical School and then the University of Vermont College of Medicine. It was at Vermont that he began working on Alzheimer’s disease and other age-related neurodegenerative disorders. In 1986, Dr. Perl joined the Mount Sinai School of Medicine in New York, where for 24 years he served as Director of the Neuropathology Division and was Professor of Pathology, Psychiatry, and Neurosciences.
Professor Perl has authored over 270 peer-reviewed publications and book chapters and is co-author, with Professor Margaret Esiri, of the 3rd edition of Oppenheimer’s Diagnostic Neuropathology, one of the leading textbooks in his field. He is highly regarded for his work on various aspects of the neuropathology of age-related neurodegenerative disorders, especially the role of environmental factors in their induction. He has pioneered the study of the potential role of several metallic elements in association with a variety of brain disorders. In 2007, he founded Sideromics LLC to develop concepts of altering iron-related metabolism in micro-organisms as an approach to controlling their growth. Prior to coming to Uniformed Services University of the Health Sciences, his research had been continually funded by the National Institutes of Health for 32 years. Professor Perl has won numerous awards for his research as well as his role as a medical educator.
In September 2010, Professor Perl left Mount Sinai to join the faculty of the Uniformed Services University of the Health Sciences in Bethesda, MD. In conjunction with the congressionally mandated Center for Neuroscience and Regenerative Medicine, he has established a neuropathology laboratory dedicated to research on the acute and long-term effects of traumatic brain injury and PTSD among military personnel.
Dr. Daniel Perl, a co-founder of Sideromics, said: “I am excited about working with the distinguished and experienced scientists on our Scientific Advisory Board and look forward to their help in developing our new antimicrobial compounds and bringing them to the bedside.”
Gerald H. Sokol MD, MSc, FCP
Indiana University, MD, MSc Pharmacology
Chief Radiation Oncology, Tampa General Hospital
Senior Scientist - CDER
Board Director FCI/New Hope Cancer Center
Medical Director Everest University
Assistant Prof of Medicine and Clinical Pharmacology USUHS
Lifetime Board Member American Cancer Society
Gerald H. Sokol MD, MSc, FCP attained his medical degree from Indiana University’s Combined Degree Program in Experimental Medicine with a Master’s Degree in Pharmacology and is recognized internationally for his work on advancing the treatment of skin cancer. Dr. Sokol interned in Medicine at Temple University and attended the US Public Health Service Hospital in affiliation with the National Cancer Institute, Johns Hopkins, and the University of Maryland completing training in Internal Medicine. He then completed training at the Massachusetts General Hospital, Harvard Medical School in Radiation Oncology, Medical Oncology and Clinical Pharmacology attaining Board Certification in Internal Medicine, Medical Oncology, Radiation Oncology, Clinical Pharmacology, and later - Quality Assurance and Utilization Review. In addition, he is certified in Skin Cancer Medicine from the University of Queensland.
Dr. Sokol has been Chief of Radiation Oncology at the University of South Florida’s Tampa General Hospital and has built or contributed to building over 10 highly successful cancer centers. He is also a board member and partner of Florida Cancer Specialists and Research Institute (the largest research group in Florida) consisting of over 190 physicians.
Dr. Sokol is a decorated retired Captain in the US Navy and served as Commanding Officer of the unit at the Uniformed Services University and currently holds professorships in Medicine and Pharmacology at that institution. While maintaining a busy medical practice, Dr. Sokol served on the review staff of the FDA for 27 years as a senior regulatory scientist and officer composing over 300 white papers, IND and NDA reviews, and opinion papers. Dr. Sokol has authored or coauthored over 100 books, book chapters, abstracts and papers on a multitude of clinical issues. He is a lifetime fellow and board member of the American Cancer Society and a fellow of the American College of Clinical Pharmacology.
Dr. Jordi Vila
Professor of Microbiology
Head of the Department at the University of Clinical Microbiology School of Medicine
University of Barcelona Barcelona
Dr. Vila is currently the Head of the Department of Clinical Microbiology of the Hospital Clinic in Barcelona, Full Professor of the School of Medicine, University of Barcelona, and Research Professor in the Institute for Global Health of Barcelona, Spain. His present main field of interest is in the investigation of the molecular bases of antimicrobial resistance and the development of new drugs against bacteria and molecular tools and the detection of biomarkers for rapid diagnosis of infectious disease.
Dr. Vila was the Programme Director of the Congress of the European Society of Clinical Microbiology (ESCMID) from 2009 to 2014 and he has been for 4 years a member of the ICAAC Scientific Program Committee. He has published 375 articles in peer-reviewed journals, 42 book chapters and directed 19 doctoral theses (number of citations, 14,507 and H-index of 66, according to Google Scholar). He has patented two molecules.
Barak Yahalom, DVM
Co-Founder, Chief Executive Officer, and Chief Scientific Officer at Alpha Preclinical LLC.
North Grafton, MA
Barak is a Doctor of Veterinary Medicine with over 20 years of Clinical Research Organization and Biotechnology experience. He obtained his Doctor of Veterinary Medicine and Bachelor of Science in Animal Science degrees from Hebrew University, Jerusalem, Israel. His expertise includes in vivo preclinical animal models, as well as surgical modes, pharmacokinetics and pharmacodynamics, tolerability, preliminary toxicology, autoimmunity (i.e., systemic lupus erythematosus, experimental autoimmune encephalomyelitis, inflammatory bowel disease, arthritis), central nervous system disorders, oncology, diabetes, and gene therapy for rare diseases.
At Alpha Preclinical, Barak brings scientific knowledge and veterinary experience from the biotechnology and preclinical contract researcher industry to focus on the growth, expansion, and advancement of our portfolio companies. Barak is a founding member of Alpha’s scientific team and serves as the company’s Chief Executive Officer and Chief Scientific Officer. He has contributed research to seven scientific publications and is experienced in client-based and program revenue expansion, customer engagement, supervision and mentorship of Study Directors, Research Associates, and Animal Care Technicians, as well as medical and scientific informational support for study design development. Prior to Alpha, Barak held the responsibility as director of in vivo pharmacology at multiple biotech companies, and positions of increasing responsibility at Boston Children’s Hospital and Biomere. He conducted his veterinary training at the Hebrew University of Jerusalem, Israel.
Vitomir Djokic, DVM, Ph.D.
Tissue Regeneration Sciences
Department of Medicine, New York University School of Medicine
Vitomir is a Doctor of Veterinary Medicine with over seven years of experience collaborating with pharmaceutical companies on host immune response to bacterial and parasitic infections and new diagnostic tools and drug targets. He obtained his Doctor of Veterinary Medicine degree from the University of Belgrade, Serbia and the University of Veterinary Medicine in Vienna, Austria. He also obtained his Doctor of Philosophy degree in Life Science Complexity from the University Paris VI “Pierre et Marie Curie” in Paris, France. His expertise includes mammalian cell isolation, primary culture and cell line culturing and handling, serological and molecular diagnostic test development, Biosafety Lab 2 and 3 environments and corresponding regulatory guidance standards, and the design and analysis of vaccine and epidemiology studies.
Vitomir currently serves as a Research Scientist within the Department of Medicine at New York University’s School of Medicine. He has published 16 articles in peer reviewed journals (8 as first author) and has two articles currently in preparation. He also has a great deal of experience in conducting in vivo vaccine and infection kinetics studies in various animal models.
Benjamin Fontes, MPH, CBSP
Safety Advisory Manager of Environmental Health and Safety at Yale University
Biological Safety Officer of Environmental Health and Safety at Yale University
Ben has over 20 years of experience as a Certified Biological Safety Professional. He obtained his Master of Public Health degree in Industrial Hygiene from the University of Michigan’s School of Public Health in Michigan, United States. He also obtained a certificate in Public Health from Harvard’s School of Public Health/Harvard Extension School in Massachusetts, United States and serves as a Specialist Microbiologist in Biological Safety for the American Society of Microbiology’s National Registry of Microbiologists. He obtained his undergraduate degree in Biology from Wesleyan University in Connecticut, United States. His expertise includes building and managing Environmental Health and Safety (EHS) programs.
Ben currently serves as the Biological Safety Officer at Yale University, where he is responsible for the management of the campus’ Biosafety Program and co-management of the EHS Safety Advisor Program. Ben is an active member of the American Biological Safety Association, where he held the role of President, and is currently on the executive board of the International Federation of Biosafety Associations, where he has served as Chair from 2014 – 2017. He has worked for the past three years as a biosafety twin for new biosafety professionals in the Middle East and North Africa as part of a Sandia National Laboratories twinning and mentorship program, helping his assigned partners with guidance on their biosafety and biosecurity projects.
Shoreh Miller, DVM, PhD, DACLAM
Director of In vivo Research Services of the Comparative Medicine Services at Rutgers University
Attending Veterinarian at PMV Pharma
Member of the American College of Laboratory Animal Medicine Examination Resources Committee
Adjunct Assistant Professor of the Department of Pediatrics at Robert Wood Johnson Medical School
Shoreh is a Doctor of Veterinary Medicine with over 20 years of in vivo and in vitro research experience in academia and industry. She obtained her Doctor of Veterinary Medicine from the University of Tehran, Tehran, Iran. She also obtained her Doctor of Philosophy degree in Microbiology and Immunology from the State University of New York at Buffalo’s School of Medicine and Biomedical Sciences and was nominated as a Diplomate of the American College of Laboratory Animal Medicine Examination Resources Committee (ACLAM) in 2008. Her expertise includes molecular biology, immunology, preclinical studies, development of in vivo methods, and animal care and use regulations.
Shoreh currently serves as the Director of In vivo Research Services of the Comparative Medicine Services at Rutgers University, an attending veterinarian at PMV Pharma, a member of the ACLAM Examination Resources Committee, an AAALAC-I consultant, and an Adjunct Assistant Professor of the Department of Pediatrics at Robert Wood Johnson Medical School. She has contributed research to 17 scientific publications and 8 presentations. She also has over 15 years of experience as a laboratory animal medicine veterinarian and over 10 years of experience in project management and academia.